4-AMINOBIPHENYL

4-Aminobiphenyl was considered by previous IARC Working Groups in 1971, 1987, and 2008 (IARC, 1972, 1987, 2010). Since that time new data have become available, which have been incorporated in this Monograph, and taken into consideration in the present evaluation.

1. Exposure Data

1.1 Identification of the agent

Chem. Abstr. Serv. Name: [1,1’-Biphenyl]-4-amine

\[
\begin{array}{c}
\text{C}_{12}\text{H}_{11}\text{N} \\
\text{Relative molecular mass: 169.22} \\
\text{Description: Colourless, crystalline solid that turns purple when exposed to air} \\
\text{Solubility: Slightly soluble in cold water;} \\
\text{soluble in acetone, chloroform, ethanol,} \\
\text{diethyl ether, and hot water} \\
\text{From O’Neil (2006), Lide (2008), and IARC (2010)}
\end{array}
\]

1.2 Uses

4-Aminobiphenyl has been used in the past as a rubber antioxidant, as a dye intermediate, and in the detection of sulfates. It is reportedly used as a model carcinogen in mutagenicity studies and in cancer research (NTP, 2005; O’Neil, 2006; HSDB, 2009).

1.3 Human exposure

1.3.1 Occupational exposure

Historically, occupational exposure to 4-aminobiphenyl mainly occurred during its production and its use as a rubber antioxidant and dye intermediate. No exposure measurements are available for these occupational exposure situations (IARC, 2010).

Occupational exposure can also occur when workers are exposed to products contaminated with 4-aminobiphenyl, or in the case of exposure to benzidine and benzidine-based dyes, from which 4-aminobiphenyl can be metabolically released (IARC, 2010). In a study from India on workers exposed to benzidine or benzidine-based dyes and a non-exposed control group, urine samples were analysed for 4-aminobiphenyl and acetylated 4-aminobiphenyl (Ac4ABP). 4-Aminobiphenyl was found in 30 of 33 urine samples from exposed workers and in one sample from the 13 control workers. The workers exposed to benzidine had significantly higher median 4-aminobiphenyl concentrations (57 pmol/mL) than those exposed to benzidine-based dyes (29.3 pmol/mL). Ac4ABP was only detected (79.5 pmol/mL) in the urine sample that was provided by the person who had the highest 4-aminobiphenyl concentration (Beyerbach et al., 2006).
1.3.2 Non-occupational exposure

The main sources of exposure to 4-aminobiphenyl for the general population are cigarette smoking and second-hand tobacco smoke, as 4-aminobiphenyl is formed during tobacco combustion. The following amounts of 4-aminobiphenyl have been reported in unfiltered mainstream, filtered mainstream and side-stream cigarette smoke, respectively: 2.4 to 4.6 ng/cigarette; 0.2 to 23 ng/cigarette; and up to 140 ng/cigarette (Patrianakos & Hoffmann, 1979; Hoffmann et al., 1997).

Other potential sources include hair dyes and food colourant. 4-Aminobiphenyl can occur as a contaminant in 2-aminobiphenyl, which is used in the manufacture of dyes. 4-Aminobiphenyl has been detected in aniline, in the drug and cosmetic colour additive D&C Yellow No. 1, in the food dye FD&C Yellow No. 6, and in hair dyes (Richfield-Fratz et al., 1985; Chiang et al., 1999; Turesky et al., 2003; Akyüz, 2007; Bafana et al., 2007). 4-Aminobiphenyl has also been found as a contaminant in diphenylamine, a fungicide that has been used on apples.

4-Aminobiphenyl has been detected in fume from cooking oils. In a study from Taiwan, China, concentrations of 4-aminobiphenyl were 35.7 μg/m³ in fumes from cooking with sunflower oil, 26.4 μg/m³ in vegetable oil fumes and 23.3 μg/m³ in oil fumes from refined lard (Chiang et al., 1999).

Living near benzidine-contaminated sites may result in exposure to 4-aminobiphenyl, as benzidine in the environment can be degraded to 4-aminobiphenyl by certain bacteria (Bafana et al., 2007).

2. Cancer in Humans

2.1 Descriptive studies

Melick et al. (1955) reported a series of 19 cases of cancer of the urinary bladder in 171 male workers (11.1%) engaged in the production of 4-aminobiphenyl. The exposure took place in a chemical plant in the United States of America (USA) between 1935 and 1955. In a follow-up study it was reported that among 315 male workers exposed to 4-aminobiphenyl, 53 had developed bladder tumours (Melick et al., 1971).

2.2 Cohort studies

Following the cessation of industrial production of 4-aminobiphenyl in 1955, a surveillance programme in exposed workers revealed 31 of 285 men with significantly abnormal epithelial cells in urinary sediments, of whom ten were diagnosed with histologically confirmed bladder carcinoma (Melamed et al., 1960). Subsequently, 11 additional cases were found among 18 of the men reported in 1960 to have abnormal cells (Koss et al., 1965). Expanded surveillance programmes identified 35 workers with cancer of the urinary bladder among 503 workers (Koss et al., 1969) and 43 men with confirmed bladder carcinoma among 86 men with suspicious or positive histology (Melamed, 1972).

Cancer mortality was studied among 884 male workers at a chemical plant in West Virginia (USA) that produced a variety of chemicals. A tenfold increase in mortality from bladder cancer was reported, with all nine cases having started work before 4-aminobiphenyl production ceased in the plant in 1952 (Zack & Gaffey, 1983). An analysis of mortality through 1987 showed 11 deaths from cancer of the urinary bladder among workers in jobs with possible exposure to 4-aminobiphenyl, compared to 0.54 expected (Collins et al., 1993).

Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin
4-Aminobiphenyl was also considered, based on reports of chloracne related to an industrial accident with TCDD in 1949, but ten of the 11 workers who died of cancer of the urinary bladder did not have chloracne. Collins et al. (1999) conducted another cohort study in the same plant and evaluated the risk for cancer of the urinary bladder associated with exposure to 4-aminobiphenyl and another bladder carcinogen, 2-mercapto­benzothiazole (MBT). Eight workers in jobs with exposure to 4-aminobiphenyl and MBT died of cancer of the urinary bladder, 0.3 deaths were expected (SMR 27.1; 95%CI: 11.7–53.4), while five workers exposed to MBT in jobs associated with little or no exposure to 4-aminobiphenyl died of cancer of the urinary bladder, compared with 1.2 expected.

2.3 Synthesis

Case reports and cohort-surveillance studies indicate a high occurrence of cancer of the urinary bladder in workers occupationally exposed to 4-aminobiphenyl, supported by evaluations of mortality in a chemical plant in the USA. Bladder cancer is strongly associated with occupational exposure to 4-aminobiphenyl.

3. Cancer in Experimental Animals

Studies on the carcinogenicity of 4-aminobiphenyl in the mouse, rat, dog, and rabbit after oral administration or after subcutaneous or intraperitoneal injection have been reviewed in previous IARC Monographs (IARC, 1972, 1987, 2010). The results of adequately conducted carcinogenicity studies are summarized in Table 3.1. There have been no additional carcinogenicity studies in animals reported since the most recent evaluation (IARC, 2010).

4-Aminobiphenyl was tested for carcinogenicity by oral administration in three studies in mice, six studies in dogs and one study in rabbits, by subcutaneous injection in one study in mice and one study in rats and by intraperitoneal injection in four studies in mice.

Oral administration of 4-aminobiphenyl caused increased incidences of angiosarcoma (all sites) in male and female mice, bladder carcinoma in male mice (Schieferstein et al., 1985), hepatocellular carcinoma in female mice (Clayson et al., 1967; Schieferstein et al., 1985), and bladder carcinoma in male and female dogs (Walpole et al., 1954; Deichmann et al., 1958, 1965; Block et al., 1978) and in rabbits (sex not specified) (Bonser, 1962). [The Working Group noted that there were limitations in the design and reporting of these studies.] The incidence of hepatocellular adenoma and/or carcinoma was increased in male mice after subcutaneous (Gorrod et al., 1968) or intraperitoneal injection (Dooley et al., 1992; Parsons et al., 2005). [Most of these studies were designed to study tumour formation in the liver and the histopathology is limited to examination of the liver only.]

4. Other Relevant Data

4.1 Aromatic amines: metabolism, genotoxicity, and cancer susceptibility

Biotransformation pathways and genotoxic effects of aromatic amines are described in detail in IARC (2010); highlights are summarized below.

Exposures to aromatic amines, such as 2-naphthylamine, 4-aminobiphenyl and benzidine in the textile dye and rubber tyre industries have long been known to cause cancer of the urinary bladder in humans. These substances also induce neoplasms at multiple organ sites in laboratory animals. Tobacco smoke and hair dyes are major non-occupational sources of exposure to
Table 3.1 Carcinogenicity studies of 4-aminobiphenyl in experimental animals

<table>
<thead>
<tr>
<th>Species, strain (sex)</th>
<th>Duration</th>
<th>Reference</th>
<th>Route</th>
<th>Dosing regimen, Animals/group at start</th>
<th>Incidence of tumours</th>
<th>Significance</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse C57 x IF1 (M, F)</td>
<td>70 wk</td>
<td>Clayson et al. (1967)</td>
<td>Oral—Gavage</td>
<td>A group of 21 M and 28 F mice were dosed with 0.2 ml of a 25% 4-aminobiphenyl solution in arachis oil, twice/wk for 50 wk, and kept for an additional 20 wk. A group of 19 M and 31 F served as untreated controls</td>
<td>Hepatoma, malignant: M–0/19, 4/21; F–0/31, 13/28* Bladder carcinoma: M–0/19, 1/21; F–0/31, 0/28</td>
<td>No statistics *[P &lt; 0.0001]</td>
<td>Also reported were four “probably malignant” hepatomas in female mice. Purity of 4-aminobiphenyl NR</td>
</tr>
<tr>
<td>Mouse BALB/cStGrCrlfC3Hf/ Nctr (M, F)</td>
<td>96 wk</td>
<td>Schieferstein et al. (1985)</td>
<td>Oral—Drinking-water</td>
<td>Groups of 120 M and 120 F mice were given 4-aminobiphenyl as the hydrochloride salt (&gt; 99.5% pure) at doses of 0, 7, 14, 28, 55, 110, and 220 ppm (M) and 0, 7, 19, 38, 75, 150, and 300 ppm (F). Interim sacrifices were at 13, 26, 39, 52, and 96 wk</td>
<td>Angiosarcoma (all sites): M–1/118, 1/117, 1/118, 2/119, 4/115, 5/119, 14/118* F–1/119, 4/120, 4/120, 2/120, 14/120, 26/118, 11/117* Bladder carcinoma: M–0/116, 1/117, 1/118, 0/118, 6/115, 15/118, 23/118* F–0/118, 0/118, 0/119, 1/118, 0/118, 5/117, 1/117 Hepatocellular carcinoma: M–2/118, 1/117, 0/118, 0/117, 0/114, 3/118, 2/117 F–0/117, 0/120, 2/120, 4/119, 10/119, 14/118, 7/117*</td>
<td>*P &lt; 5x10⁻⁵, positive trend</td>
<td></td>
</tr>
<tr>
<td>Dog Beagle (M)</td>
<td>33 mo</td>
<td>Walpole et al. (1954)</td>
<td>Oral</td>
<td>Two, 7 mo-old male dogs were given 4-aminobiphenyl in a gelatin capsule once daily, 6 × /wk until termination of the study. The dose level was lowered during the course of the experiment and dosing was also interrupted temporarily for 6 mo. The experiment was terminated after 33 mo; total dose for the two dogs was 2.9 and 3.3 g/kg bw, respectively</td>
<td>Bladder carcinomas occurred in both dogs</td>
<td>NR</td>
<td>No concurrent controls. Historical data from this laboratory show that thirty Beagle dogs (age, 3–9 yrs) that died of various causes did not develop bladder tumours. Purity of 4-aminobiphenyl NR</td>
</tr>
<tr>
<td>Species, strain (sex)</td>
<td>Route</td>
<td>Incidence of tumours</td>
<td>Significance</td>
<td>Comments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>-------</td>
<td>----------------------</td>
<td>--------------</td>
<td>----------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dog Mongrel (F)</td>
<td>Oral</td>
<td>Bladder carcinomas occurred in all four dogs after 21–34 mo</td>
<td>NR</td>
<td>No concurrent controls. Experimental design poorly described. Bladder is only tissue examined.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dog Beagle (F)</td>
<td>Oral</td>
<td>Bladder carcinomas (transitional cell type) were observed in three dogs, bladder papillomas in the three other dogs.</td>
<td>NR</td>
<td>No concurrent controls. Bladder is only tissue examined. Purity of 4-aminobiphenyl NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dog Beagle (F)</td>
<td>Oral</td>
<td>Transitional cell urinary bladder carcinomas 20/24 Grade-2 and -3 tumours 2/24 Grade-1 tumours 2/24 no detectable tumours</td>
<td>Authors indicate that twenty matched littermates served as controls, but no other information was provided for the control animals. Purity of 4-aminobiphenyl NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabbit Strain NR (sex NR)</td>
<td>Oral</td>
<td>Bladder carcinoma: 0/12, 3/7</td>
<td>NR [P &lt; 0.036]</td>
<td>Experimental design very poorly described. It appears bladder is the only tissue examined. Sex NR. Purity of 4-aminobiphenyl NR Dose and dose regimen NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse Swiss (M, F)</td>
<td>Subcutaneous injection</td>
<td>Male Hepatomas: M–5/41, 19/20 F–2/41, 4/23</td>
<td>NR [P &lt; 0.0001][NR]</td>
<td>Purity of 4-aminobiphenyl NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Species, strain (sex)</td>
<td>Duration</td>
<td>Reference</td>
<td>Route</td>
<td>Incidence of tumours</td>
<td>Significance</td>
<td>Comments</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>----------</td>
<td>-----------</td>
<td>-------</td>
<td>----------------------</td>
<td>--------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>Lifetime (animals kept for up to 582 d)</td>
<td>Walpole et al. (1952)</td>
<td>Subcutaneous injection</td>
<td>Groups of 11 M and 12 F rats were each divided in two groups and given 4-aminobiphenyl in arachis oil 5 x /wk for a mean duration of 250–376 dosing d, to a total mean dose per animal of 3.6–5.8 g/kg bw. A control group of 12 M and 11 F rats received arachis oil only.</td>
<td>Intestinal tumours</td>
<td>M–0/12, 3/6 (4.4 g/kg bw), 1/5 (5.8 g/kg bw) F–1/11, 1/6 (3.6 g/kg bw), 2/6 (4.2 g/kg bw)</td>
<td>Experimental design, especially exposure durations, poorly described. Small numbers of animals make study results difficult to interpret.</td>
</tr>
<tr>
<td>Mouse</td>
<td>12 mo</td>
<td>Dooley et al. (1992)</td>
<td>Intraperitoneal injection</td>
<td>Newborn male mice were given 4-aminobiphenyl (&gt; 98%). The amounts administered were 0, 0.625 and 1.25 μmol dissolved in 35 μl DMSO, injected in portions of 5, 10 and 20 μl on d 1, 8 and 15 after birth, respectively. Surviving pups were weaned on d 21 and designated for necropsy at 8 or 12 mo of age.</td>
<td>At 12 mo: Hepatocellular adenomas: 5/44, 19/19*, 15/15* Hepatocellular carcinomas: 0/44, 5/19**, 5/15* At 8 mo: Hepatocellular adenomas: 1/44, 22/24*, 8/11* No carcinomas</td>
<td>*P &lt; 0.001, Fisher exact test), **P &lt; 0.005</td>
<td>Initial number of animals NR</td>
</tr>
<tr>
<td>Mouse</td>
<td>12 mo</td>
<td>Parsons et al. (2005)</td>
<td>Intraperitoneal injection</td>
<td>Newborn male mice were given 0.3 μmol 4-aminobiphenyl dissolved in DMSO, by a series of injections: 1/7th of the dose on postnatal Day 1, 2/7th on Day 8, and 4/7th on Day 15. Control mice received DMSO only.</td>
<td>Hepatocellular adenoma: 4/18, 19/24 Hepatocellular carcinoma: 0/18, 2/24</td>
<td>*P &lt; 0.001</td>
<td>Liver is the only tissue examined. Initial number of animals NR</td>
</tr>
<tr>
<td>Mouse</td>
<td>12 mo</td>
<td>Von Tungeln et al. (1996)</td>
<td>Intraperitoneal injection</td>
<td>Newborn male mice were given a total dose of 625 nmol 4-amino-biphenyl (&gt; 99% pure) in 35 μl dimethyl sulfoxide, given in portions of 5, 10 and 20 μl on Days 1, 8, and 15 after birth, respectively. At weaning, the animals were divided over two groups, which were fed ad libitum until the age of 14 wk. Thereafter, one group received 90% of the calories of the ad libitum feeding regimen during one wk, followed by 75% of the calories during one wk, and then 60% of the calories in the diet until sacrifice at 12 mo.</td>
<td>Ad-libitum group: Hepatocellular carcinoma: 6/22 Hepatocellular adenoma: 12/22 Caloric restriction group: Liver tumours: 0/19</td>
<td>P &lt; 0.02 Between ad libitum and caloric restriction groups</td>
<td>No tumours in calorie-restricted group</td>
</tr>
<tr>
<td>Species, strain (sex)</td>
<td>Route</td>
<td>Incidence of tumours</td>
<td>Significance</td>
<td>Comments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------</td>
<td>----------------------</td>
<td>--------------</td>
<td>----------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse CYP1A2 −/− and CYP1A2+/+ (M, F) 16 mo</td>
<td>Intraperitoneal injection</td>
<td>Hepatocellular carcinoma: −/− M–0/12, 5/27, 8/42 +/+ M–0/12, 6/30, 4/26 −/− F–0/25, 0/25, 0/27 +/+ F–0/25, 1/23, 0/33</td>
<td>*P &lt; 0.01 **P &lt; 0.05</td>
<td>Liver was the only tissue examined. Initial number of animals NR Mice derived from a mixed background of 129/Sv and C57BL/6 strains</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

bw, body weight; d, day or days; DMSO, dimethyl sulfoxide; F, female; M, male; mo, month or months; NR, not reported; wk, week or weeks; yr, year or years
arylamines, as is demonstrated by the detection of aminobiphenyl-haemoglobin adducts (Bryant et al., 1988; Ward et al., 1996; Beyerbach et al., 2006), which can be 3- to 10-fold more abundant in tobacco smokers than in nonsmokers (Yu et al., 2002). Other environmental sources of exposure are likely to exist as well, because biomarkers derived from aromatic amines, such as haemoglobin adducts or urinary metabolites have been identified also in non-smokers who are not occupationally exposed to these chemicals.

Multiple metabolic pathways are involved in the activation of aromatic amines to DNA-reactive intermediates. Metabolism is initiated in the liver with either N-oxidation (by cytochrome P-450-associated enzymes) or N-acetylation (by N-acetyltransferase 2, NAT2). N-oxidation to N-hydroxyarylamine is mainly mediated by CYP1A2, but also CYP1A1 and CYP4B1 iso-enzymes may play a role (Landi et al., 1996; Ketelslegers et al., 2009). NAT2-catalysed N-acetylation can provide a detoxification pathway for aromatic amines since it reduces the amount of parent compound that may undergo CYP-mediated N-hydroxylation. The N-hydroxy metabolite is highly electrophilic: N-hydroxyaminobiphenyl, the oxidation product of 4-aminobiphenyl (4-ABP) forms adducts with hepatic DNA at the C8 position of deoxyguanosine and deoxyadenosine in rats (Jones & Sabbioni, 2003). N-hydroxyarylamines may be transported in free form to the blood or be conjugated with glucuronide. The acid-labile glucuronidated intermediate is excreted via the kidney and hydrolysed in the bladder lumen where it eventually forms the N-hydroxy metabolite again. The acidic pH of urine enhances the hydrolysis reaction and thus represents an additional risk factor for aromatic amine-related bladder cancer. NAT1-mediated O-acetylation may represent the final activation step of N-hydroxyarylamines; it takes place in the bladder epithelium and forms N-acetoxyarylamine. Breakdown of this unstable aromatic acetoxy ester produces the highly reactive aryl nitrenium ion that may serve as electrophilic intermediate leading to DNA adducts and tumour initiation. The highly active NAT1*10 isoform was correlated with higher levels of arylamine-DNA adducts in the human bladder (Kadlubar & Badawi, 1995).

Other activation pathways of aromatic amines to DNA-reactive intermediates include the sulfotransferase-mediated activation of N-hydroxyarylamine to an N-sulfate ester (Chou et al., 1995), the peroxidative activation by prostaglandin H synthase (Flammang et al., 1989) – likely predominant in extra-hepatic tissues with low levels of cytochrome P450 isoenzymes –, and non-enzymatic protonation of the N-hydroxylamine nitrogen (Beland et al., 1983). Genotoxic aromatic amines may induce tumour formation at different sites depending on substrate specificity and different bio-activation pathways. Inter-individual variability in prostaglandin H synthases in the urinary bladder and in myeloperoxidases in the lung may account for differences in target-site susceptibility to aromatic amines in cigarette smokers (Flammang et al., 1989).

The genotoxic effects of aromatic amines are well established on the basis of mutagenicity and clastogenicity observed in numerous in vitro and in vivo assays that show the capability of these compounds to form DNA adducts after metabolic activation to electrophilic intermediates. The predominant site for covalent binding of aromatic amines to DNA is the C8 position of guanine, but adducts at other sites, including C8 of adenine and N2 of guanine, have also been identified (Beland et al., 1983; Kaderlik et al., 1993; Lin et al., 1994; Rothman et al., 1996a). As DNA adducts may lead to somatic point mutations, it is reasonable to assume that activated aromatic amines may lead to bladder-tumour development by inducing mutations in key genes.
such as the TP53 tumour suppressor gene (Sørlie et al., 1998; Feng et al., 2002) and the H-RAS gene (Boulalas et al., 2009), both involved in bladder carcinogenesis.

Organ specificity and inter- and intra-species differences in cancer susceptibility to aromatic amines are likely related to polymorphisms in genes that regulate DNA-repair, since deficient DNA-repair capacity is associated with increased bladder cancer risk (Lin et al., 2005), and to polymorphisms in genes that encode enzymes involved in activation or detoxification pathways. The NAT2 slow-acetylator genotype accounts for a greater risk for cancer of the urinary bladder in individuals exposed to 2-naphthylamine or 4-aminobiphenyl (Yu et al., 2002) and for a lower risk in workers exposed to benzidine (Carreón et al., 2006). Conflicting findings between studies may be a consequence of the interdependence of pathways of arylamine metabolism and of the capability of N-acetyltransferases both to detoxify the parent compound and to activate metabolites at different rates in different tissues.

4.2 4-Aminobiphenyl

N-hydroxylation of 4-aminobiphenyl (4-ABP) in human and rat-liver microsomes is primarily catalysed by CYP1A2 (Kimura et al., 1999), an enzyme with a large inter-individual variability (Butler et al., 1989), and by extra-hepatic cytochrome P450s including CYP1A1, CYP1B1, and CYP2A13 (Shimada et al., 1996; Nakajima et al., 2006). In extra-hepatic tissues, the binding of 4-ABP to DNA may be catalysed by peroxidase enzymes, such as prostaglandin H synthase (Flammang et al., 1989).

The major 4-ABP-DNA adduct identified in human bladder and lung is N-(deoxyguanosin-8-yl)-4-ABP (Lin et al., 1994): other adducts include N-(deoxyadenosin-8-yl)-4-ABP and N-(deoxyguanosin-N2-yl)-4-ABP (Beland et al., 1983). N-(deoxyguanosin-8-yl)-4-ABP has also been detected in female breast tissue of both smokers and non-smokers (Lin et al., 1994; Faraglia et al., 2003) indicating that 4-ABP-reactive intermediates are distributed systemically and/or that multiple organs are capable of activating 4-ABP or its metabolites. Experiments in animals show that 4-ABP induces bladder tumours in mice, rabbits, and dogs, liver tumours, mammary gland tumours and angiosarcomas in mice, and intestinal tumours in rats. Increased levels of 4-ABP-haemoglobin adducts are associated with cigarette smoking (Bryant et al., 1988), and occupational exposure to 4-ABP is associated with an increased risk for cancer of the urinary bladder (Beyerbach et al., 2006).

To explore the role of various metabolic intermediates in the mutagenicity of aromatic amines, the DNA-damaging potential of 4-ABP was studied in different bacterial strains. In S. typhimurium in the presence of S-9-mediated metabolic activation, 4-ABP was found to induce mutations such as frameshifts and base substitutions in TA98 and TA100 strains, respectively (Chung et al., 2000), and oxidant-induced mutations in TA102, suggesting an oxidative mechanism (Makena & Chung, 2007). 4-ABP-induced DNA damage was mainly due to activation by NAT1 (Oda, 2004) and was increased with higher O-acetylation activity (Dang & McQueen, 1999), thus demonstrating the potentially important role of N-acetoxy-4-ABP in the mutagenicity of this aromatic amine. In E. coli, 4-ABP induced base-pair substitutions predominantly at G sites, including G→T, G→C transitions, and G→A transitions (Verghis et al., 1997). In addition, G→C transversion mutations were triggered by incorporating an oligonucleotide containing the N-(deoxyadenosin-8-yl)-4-ABP adduct into the single-stranded DNA of the cloning vector, demonstrating the role of this adduct in 4-ABP-induced mutagenesis.

4-ABP induced mutations at the HPRT locus and chromosomal instability in human bladder epithelial cells. In 4-ABP-induced liver tumours in B6C3F1 and CD-1 mice, primarily C→A and A→T
mutations, respectively, were detected at codon 61 of the H-Ras gene. 4-ABP also increased the mutation frequency in the bladder, liver, and bone marrow of mice. In human bladder cells treated with N-hydroxy-4-ABP, preferential sites of adduct formation in TP53 were at codons 175, 248, 280, and 285, which are mutational hotspots for cancer of the urinary bladder (Feng et al., 2002).

5. Evaluation

There is sufficient evidence in humans for the carcinogenicity of 4-aminobiphenyl. 4-Aminobiphenyl causes cancer of the urinary bladder.

There is sufficient evidence in experimental animals for the carcinogenicity of 4-aminobiphenyl.

There is strong mechanistic evidence indicating that the carcinogenicity of 4-aminobiphenyl in humans operates by a genotoxic mechanism of action that involves metabolic activation, formation of DNA adducts, and induction of mutagenic and clastogenic effects. Metabolic activation to DNA-reactive intermediates occurs by multiple pathways including N-oxidation in the liver, O-acetylation in the bladder, and peroxidative activation in the mammary gland and other organs.

4-Aminobiphenyl is carcinogenic to humans (Group 1).

References


Block NL, Sigel MM, Lynne CM et al. (1978). The initiation, progress, and diagnosis of dog bladder cancer induced by 4-aminobiphenyl. *Invest Urol*, 16: 50–54. PMID:689839


